 |
|
UCSF marks a milestone with 500th transplant in heart and lung program
April 25, 2008UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
"We're glad to reach this significant point in our program because it means that a great number of patients are receiving improvements to their health that could not otherwise be achieved without an organ transplant," said Charles Hoopes, MD, director of Cardiopulmonary Transplantation at UCSF since 2002. "UCSF has a highly experienced transplant support team and is dedicated to research focused on continued improvement in patient survival and outcomes for transplanted organs."
Patients in the program have undergone either a heart or lung transplant or both.
According to UCSF clinical specialists, transplant is the best treatment for patients with severe, end-stage disease where no effective medical or nontransplant surgical treatments are available.
Conditions that damage the heart to the point where a transplant is the best chance for improved health include congenital heart disease, coronary artery disease, heart failure, pulmonary hypertension, and valvular heart disease. Severe diseases of the lung that can lead to transplant include emphysema, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension, and sarcoidosis, an inflammation that produces tiny lumps in the lungs.
In January, new data from the Scientific Registry of Transplant Recipients showed that UCSF exceeded national averages for expected survival rates of both heart and lung transplant patients. Known for tackling complex transplant surgeries, UCSF was the only hospital among the U.S. News & World Report top 18 hospitals that exceeded the national averages in both heart and lung transplant programs (http://www.ustransplant.org/).
Research is making it possible for more patients with uncommon disease types to receive transplants.
"Part of the benefit of being at UCSF is to work on the cutting edge of research, to never be satisfied with the status quo and to identify new recipient populations, new science, and new ways of improving care," said Jeffrey Golden, MD, medical director of the UCSF Lung Transplant Program. "Our transplant population includes patients with unique rheumatological disorders and those with end stage lung disease secondary to congenital heart disease--patients with diseases that are just now being considered viable for transplantation."
Research in transplant medicine has been a focus of the UCSF transplant program since it began. UCSF researchers are presently investigating a blood test instead of a biopsy to identify patients who might reject their donor organ and the future possibility of using inhaled immunosuppressants to stop transplant rejection. The Thoracic Transplant Program is also looking into diseases like scleroderma, a chronic autoimmune disease in which the body attacks itself to create both end stage heart and lung disease.
The Heart Transplant Program at UCSF is researching the genomics of heart failure and donor organ rejection. The program began in 1989 and focuses on pulmonary hypertension and right ventricular failure, combined heart-kidney transplant, transplant for Chagas disease, transplant for congenital heart disease, and transplant for patients with heart failure and HIV.
The UCSF Lung Transplant Program began in 1991 and is a specialized center of excellence for treating cystic fibrosis and pulmonary hypertension. The program also focuses on ECMO (extracorporeal membrane oxygenation) as a bridge to transplant for acute respiratory failure, the role of transplant in malignancy (bronchoalveolar carcinoma), and transplant for HIV patients. Current research includes the genomics of transplant rejection, acute lung injury and fungal infections.
Information about all UCSF transplant programs can be found at: http://www.ucsfhealth.org/adult/medical_services/organ_transplants.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
The University of California, San Francisco
According to UCSF clinical specialists, transplant is the best treatment for patients with severe, end-stage disease where no effective medical or nontransplant surgical treatments are available.
Conditions that damage the heart to the point where a transplant is the best chance for improved health include congenital heart disease, coronary artery disease, heart failure, pulmonary hypertension, and valvular heart disease. Severe diseases of the lung that can lead to transplant include emphysema, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension, and sarcoidosis, an inflammation that produces tiny lumps in the lungs.
In January, new data from the Scientific Registry of Transplant Recipients showed that UCSF exceeded national averages for expected survival rates of both heart and lung transplant patients. Known for tackling complex transplant surgeries, UCSF was the only hospital among the U.S. News & World Report top 18 hospitals that exceeded the national averages in both heart and lung transplant programs (http://www.ustransplant.org/).
Research is making it possible for more patients with uncommon disease types to receive transplants.
"Part of the benefit of being at UCSF is to work on the cutting edge of research, to never be satisfied with the status quo and to identify new recipient populations, new science, and new ways of improving care," said Jeffrey Golden, MD, medical director of the UCSF Lung Transplant Program. "Our transplant population includes patients with unique rheumatological disorders and those with end stage lung disease secondary to congenital heart disease--patients with diseases that are just now being considered viable for transplantation."
Research in transplant medicine has been a focus of the UCSF transplant program since it began. UCSF researchers are presently investigating a blood test instead of a biopsy to identify patients who might reject their donor organ and the future possibility of using inhaled immunosuppressants to stop transplant rejection. The Thoracic Transplant Program is also looking into diseases like scleroderma, a chronic autoimmune disease in which the body attacks itself to create both end stage heart and lung disease.
The Heart Transplant Program at UCSF is researching the genomics of heart failure and donor organ rejection. The program began in 1989 and focuses on pulmonary hypertension and right ventricular failure, combined heart-kidney transplant, transplant for Chagas disease, transplant for congenital heart disease, and transplant for patients with heart failure and HIV.
The UCSF Lung Transplant Program began in 1991 and is a specialized center of excellence for treating cystic fibrosis and pulmonary hypertension. The program also focuses on ECMO (extracorporeal membrane oxygenation) as a bridge to transplant for acute respiratory failure, the role of transplant in malignancy (bronchoalveolar carcinoma), and transplant for HIV patients. Current research includes the genomics of transplant rejection, acute lung injury and fungal infections.
Information about all UCSF transplant programs can be found at: http://www.ucsfhealth.org/adult/medical_services/organ_transplants.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
The University of California, San Francisco
Lung Transplant News and Current Lung Transplant Events RSSNew clinical trial for patients with asbestos-associated lung cancer
The Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center is now recruiting patients for a clinical research study of a new targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the lung's lining that is almost always caused by previous exposure to asbestos.
Depression and PTSD symptoms in caregivers of lung transplant patients
Symptoms of depression and post-traumatic stress disorder (PTSD) among caregivers of deceased lung transplant patients are four-to-five times more prevalent than in the average population, according to researchers who analyzed the stress levels of caregivers, as well as their perceptions of the transplant recipients' quality of dying and death.
Lung transplants in cystic fibrosis patients with life-threatening bacteria sparks debate at ISHLT
During Wednesday's Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF.
Biomarkers may reduce need for biopsies
Data presented at this week's 28th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) suggest the potential of a significant impact of using biomarkers to reduce the need for biopsies and personalize transplant patient care.
Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers
Researchers at Henry Ford Hospital today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new option for those suffering with advanced emphysema.
Survival rates exceed national averages for UCSF heart, liver and lung transplant programs
One-year survival rates for patients receiving heart, liver and lung transplants at UCSF Medical Center exceed national averages at statistically significant levels, according to new data compiled by the Scientific Registry of Transplant Recipients (SRTR).
Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema
Researchers at Pulmonary Associates today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally invasive option for those suffering with advanced widespread emphysema.
New York Methodist Hospital to study airway bypass treatment for emphysema
New York Methodist Hospital today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new, minimally-invasive option for those suffering with advanced widespread emphysema.
Cigarettes leave deadly path by purging protective genes
A University of Rochester scientist discovered that the toxins in cigarette smoke wipe out a gene that plays a vital role in protecting the body from the effects of premature aging.
Transplant drug sirolimus shrinks tumors, improves lung function
The drug sirolimus, normally used to help transplant patients fight organ rejection, may eventually be used as a less invasive treatment for a tumor called angiomyolipomata in patients with who would otherwise face surgery.
More Lung Transplant News Articles
 | The Lung Transplantation Handbook: A Guide For Patients, Second Edition by Karen A. Couture This comprehensive, 270-page book, written by lung transplant recipient Karen A. Couture, covers the entire transplantation process from beginning to end for both lung and heart-lung transplants. This book introduces the reader, in easy-to-understand language, to the complex process of getting on the transplant waiting list and how the list works; preparing for surgery and the surgery itself;... |
 | Taking Flight: Inspirational Stories of Lung Transplantation Lung Transplantation is still relatively new compared to other transplantation surgery. The first successful heart/lung transplant took place in 1981, with the first successful single lung transplant taking place in 1983. It was not until 1986 the first successful double lung transplant takes place. Even more recent is the living lobar transplant which the first successful one being in 1990. The... |
 | A Death Retold: Jesica Santillan, the Bungled Transplant, and Paradoxes of Medical Citizenship (Studies in Social Medicine) In February 2003, an undocumented immigrant teen from Mexico lay dying in a prominent American hospital due to a stunning medical oversight—she had received a heart-lung transplantation of the wrong blood type. In the following weeks, Jesica Santillan's tragedy became a portal into the complexities of American medicine, prompting contentious debate about new patterns and old problems in... |
 | I Call My New Lung Tina: Inspiration from a Transplant Survivor by Shirley Jewett Shirley Jewett is a lung transplant survivor who has taken the wealth of information she learned in her process of moving from a death sentence to a rich full life and chonicled it to encourage others who are in a similar... |
 | And Then We Danced by Zann The Grace of God and the extraordinary world of modern medicine, as well as love, hope and strength made our miracle possible. Each year, we would recall exactly what we were doing when the phone rang that morning. We would reminisce over each incident, right up to the time when the surgery doors swung closed behind him. It was all so remarkable; we never wanted to forget even the smallest... |
 | Lung Transplantation This book provides a detailed account of the principles and practice of contemporary lung transplantation. An accomplished, international team of contributing authors have combined their expertise to provide the latest scientific developments and clinical knowledge based on their extensive experience. The book covers pulmonary vascular and parenchymal lung disease, which necessitate... |
| I'll Take Tomorrow: The Story of a Courageous Woman Who Dared to Subject Herself to a Medical Experiment-The First Successful Heart-Lung Transplant by Mary Gohlke, Max Jennings | |
 | Living a Miracle by Randy Sims Imagine being told at the age of ten that you only had a few years to live. That's what doctors told Randy Sims in 1976. This year he celebrated his 40th birthday. This gripping tale of triumph recounts how he overcame the fires of organ failure and weathered the storms of life. Regardless of your personal situation, Randy offers hope and inspiration with practical real-world advice on how to... |
 | Blow the House Down: The Story Of My Double Lung Transplant by Michael A Taylor What is it like to receive a life-saving organ transplant? On April 13, 1997, I received new lungs. Blow the House Down details my story. It illustrates how Cystic Fibrosis affected my life and how I fought it. This book reflects the immense generosity of so many people, including my donor and her family; my family and friends; people who donate to Cystic Fibrosis research and drive major... |
| Atlas of Heart-Lung Transplantation by Amar S. Kapoor, Hillel Laks Operative techniques and strategies for the accepted modality of cardiac transplantation are depicted here from the viewpoint of the surgeon. The atlas features a unique format with emphasis on large, well-developed, full color graphics and operative photographs, all used to demonstrate the integral steps in operative techniques. Where necessary, biochemistry, histology, surgical anatomy,... |
| © 2008 BrightSurf.com |